|
CA1223831A
(en)
|
1982-06-23 |
1987-07-07 |
Dean Engelhardt |
Modified nucleotides, methods of preparing and utilizing and compositions containing the same
|
|
JP2000513230A
(ja)
*
|
1996-07-01 |
2000-10-10 |
エイ． ライト，ジム |
ハウスキーピング遺伝子の非翻訳領域由来のオリゴヌクレオチドおよび細胞増殖を調節するためのその使用方法
|
|
US6593305B1
(en)
|
1996-08-02 |
2003-07-15 |
Genesense Technologies Inc. |
Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
|
|
WO1998041231A1
(en)
*
|
1997-03-19 |
1998-09-24 |
Genesense Technologies, Inc. |
Suppression of malignancy utilizing ribonucleotide reductase r1
|
|
US6835395B1
(en)
|
1997-05-14 |
2004-12-28 |
The University Of British Columbia |
Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
|
|
EP1584681A3
(en)
*
|
1997-07-10 |
2005-11-09 |
GeneSense Technologies Inc. |
Antisense oligonucleotide sequences as inhibitors of microorganisms
|
|
US6610539B1
(en)
*
|
1997-07-10 |
2003-08-26 |
Genesense Technologies, Inc. |
Antisense oligonucleotide sequences as inhibitors of microorganisms
|
|
US6506559B1
(en)
|
1997-12-23 |
2003-01-14 |
Carnegie Institute Of Washington |
Genetic inhibition by double-stranded RNA
|
|
AUPP249298A0
(en)
|
1998-03-20 |
1998-04-23 |
Ag-Gene Australia Limited |
Synthetic genes and genetic constructs comprising same I
|
|
CA2513336A1
(en)
|
1998-03-20 |
1999-09-30 |
Benitec Australia Ltd. |
Control of gene expression in a non-human eukaryotic cell, tissue or organ
|
|
AU776150B2
(en)
*
|
1999-01-28 |
2004-08-26 |
Medical College Of Georgia Research Institute, Inc. |
Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
|
|
US6121000A
(en)
*
|
1999-02-11 |
2000-09-19 |
Genesense Technologies, Inc. |
Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
|
|
US20040138168A1
(en)
*
|
1999-04-21 |
2004-07-15 |
Wyeth |
Methods and compositions for inhibiting the function of polynucleotide sequences
|
|
US6642033B1
(en)
*
|
1999-07-20 |
2003-11-04 |
V.I. Technologies, Inc. |
Nucleic acids for detecting parvovirus and methods of using same
|
|
US6423885B1
(en)
*
|
1999-08-13 |
2002-07-23 |
Commonwealth Scientific And Industrial Research Organization (Csiro) |
Methods for obtaining modified phenotypes in plant cells
|
|
CN1301816A
(zh)
*
|
1999-12-27 |
2001-07-04 |
上海博德基因开发有限公司 |
一种新的多肽——核苷酸还原酶10和编码这种多肽的多核苷酸
|
|
AU2001240375A1
(en)
*
|
2000-03-17 |
2001-10-03 |
Benitec Australia Limited |
Genetic silencing
|
|
CA2369944A1
(en)
*
|
2001-01-31 |
2002-07-31 |
Nucleonics Inc. |
Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
|
|
DE10131148A1
(de)
*
|
2001-06-28 |
2003-01-16 |
I P L Internat Pharmaceutics L |
Xenogene Oligo- oder/und Polyribonukleotide als Mittel zur Behandlung von malignen Tumoren
|
|
EP1597365B1
(en)
*
|
2003-02-10 |
2013-10-09 |
Lorus Therapeutics Inc. |
Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in the treatment of cancer
|
|
CA2524255C
(en)
*
|
2003-03-21 |
2014-02-11 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
|
CA2526393A1
(en)
*
|
2003-05-21 |
2004-12-02 |
Genesense Technologies Inc. |
Antisense oligonucleotides directed to ribonucleotide reductase r1 and uses thereof in the treatment of cancer
|
|
WO2004106518A1
(en)
*
|
2003-05-31 |
2004-12-09 |
Genesense Technologies Inc. |
Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in the treatment of cancer
|
|
CN103495153A
(zh)
|
2003-10-23 |
2014-01-08 |
奇尼塔二有限责任公司 |
检测与抗病毒感染性有关的基因oas1中的突变的方法
|
|
AU2005203822A1
(en)
*
|
2004-01-12 |
2005-07-21 |
Lorus Therapeutics Inc. |
Antisense oligonucleotides directed to ribonucleotide reductase R2 and uses thereof in combination therapies for the treatment of cancer
|
|
WO2005115405A1
(en)
*
|
2004-04-28 |
2005-12-08 |
Molecules For Health, Inc. |
Methods for treating or preventing restenosis and other vascular proliferative disorders
|
|
IL179285A
(en)
*
|
2004-05-14 |
2011-04-28 |
Rosetta Genomics Ltd |
Micrornas and uses thereof
|
|
US7968762B2
(en)
*
|
2004-07-13 |
2011-06-28 |
Van Andel Research Institute |
Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF)
|
|
ATE518954T1
(de)
*
|
2004-08-18 |
2011-08-15 |
Lorus Therapeutics Inc |
Kleine interferierende rna-moleküle gegen ribonukleotidreduktase und ihre verwendungen
|
|
US20060185027A1
(en)
*
|
2004-12-23 |
2006-08-17 |
David Bartel |
Systems and methods for identifying miRNA targets and for altering miRNA and target expression
|
|
EP1866414B9
(en)
*
|
2005-03-31 |
2012-10-03 |
Calando Pharmaceuticals, Inc. |
Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
TW200808739A
(en)
|
2006-04-06 |
2008-02-16 |
Novartis Vaccines & Diagnostic |
Quinazolines for PDK1 inhibition
|
|
US9526707B2
(en)
*
|
2007-08-13 |
2016-12-27 |
Howard L. Elford |
Methods for treating or preventing neuroinflammation or autoimmune diseases
|
|
US20100204305A1
(en)
*
|
2007-12-11 |
2010-08-12 |
Lorus Therapeutics Inc. |
Small interfering rna molecules against ribonucleotide reductase and uses thereof
|
|
AR069798A1
(es)
|
2007-12-20 |
2010-02-17 |
Novartis Ag |
Derivados de 1, 3-tiazol, metodos para su preparacion, composiciones farmaceuticas que los comprenden y su uso en la manufactura de medicamentos para el tratamiento de enfermedades mediadas por la fosfatidilinositol 3-cinasa.
|
|
WO2010027279A2
(en)
*
|
2008-09-04 |
2010-03-11 |
Genesis Research And Development Corporation Limited |
Compositions and methods for the treatment and prevention of neoplastic disorders
|
|
US9289475B2
(en)
|
2008-11-06 |
2016-03-22 |
The Johns Hopkins University |
Treatment of chronic inflammatory respiratory disorders
|
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
|
EP2630240A1
(en)
*
|
2010-10-18 |
2013-08-28 |
Arrowhead Research Corporation |
Compositions and methods for inhibiting expression of rrm2 genes
|
|
PE20140293A1
(es)
|
2011-01-31 |
2014-03-19 |
Novartis Ag |
Novedosos derivados heterociclicos
|
|
ES2587533T3
(es)
|
2011-10-28 |
2016-10-25 |
Novartis Ag |
Derivados de purina y su uso en el tratamiento de enfermedades
|
|
SG11201406550QA
(en)
|
2012-05-16 |
2014-11-27 |
Novartis Ag |
Dosage regimen for a pi-3 kinase inhibitor
|
|
EP4000619A1
(en)
|
2013-12-06 |
2022-05-25 |
Novartis AG |
Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
|
|
US20180280370A1
(en)
|
2015-11-02 |
2018-10-04 |
Novartis Ag |
Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
|
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|